Mylan (NASDAQ:MYL) – Investment analysts at Leerink Swann increased their Q1 2018 earnings estimates for shares of Mylan in a note issued to investors on Thursday. Leerink Swann analyst A. Fadia now forecasts that the company will post earnings per share of $1.10 for the quarter, up from their previous estimate of $1.09. Leerink Swann currently has a “Market Perform” rating and a $44.00 target price on the stock. Leerink Swann also issued estimates for Mylan’s Q2 2018 earnings at $1.32 EPS, Q3 2018 earnings at $1.42 EPS, FY2018 earnings at $5.40 EPS, FY2021 earnings at $6.84 EPS and FY2022 earnings at $7.62 EPS.
Mylan (NASDAQ:MYL) last posted its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. Mylan’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.38 earnings per share.
Mylan (NASDAQ MYL) opened at $46.20 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The company has a market capitalization of $24,780.00, a PE ratio of 27.83, a price-to-earnings-growth ratio of 1.24 and a beta of 1.38. Mylan has a 1 year low of $29.39 and a 1 year high of $47.82.
In related news, CEO Heather M. Bresch sold 75,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.69% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ameriprise Financial Inc. grew its stake in Mylan by 4.0% in the second quarter. Ameriprise Financial Inc. now owns 279,428 shares of the company’s stock valued at $10,844,000 after acquiring an additional 10,861 shares during the period. FMR LLC grew its stake in Mylan by 19.8% in the second quarter. FMR LLC now owns 813,267 shares of the company’s stock valued at $31,572,000 after acquiring an additional 134,258 shares during the period. Suntrust Banks Inc. grew its stake in Mylan by 0.7% in the second quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock valued at $355,000 after acquiring an additional 60 shares during the period. Parametric Portfolio Associates LLC grew its stake in Mylan by 87.3% in the second quarter. Parametric Portfolio Associates LLC now owns 835,779 shares of the company’s stock valued at $32,445,000 after acquiring an additional 389,511 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Mylan by 20.8% in the second quarter. Dimensional Fund Advisors LP now owns 2,940,967 shares of the company’s stock valued at $114,171,000 after acquiring an additional 507,098 shares during the period. 75.07% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/29/q1-2018-eps-estimates-for-mylan-myl-increased-by-leerink-swann.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.